A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Anus | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Hodgkin's Lymphoma | Kaposi's sarcoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Mycosis Fungoides | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Pediatrics | Cervix | Urinary Bladder
What is the purpose of this trial?
This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory solid tumor or lymphoma. Part 1 will find the maximum tolerated dose (MTD)/maximum administered dose (MAD), confirm the dose, and find the recommended Phase 2 dose (RP2D) for pembrolizumab therapy. Part 2 will further evaluate the safety and efficacy at the pediatric RP2D.
- Trial withMerck Sharp & Dohme
- Start Date09/19/2016
- End Date12/31/2018
- Last Updated10/15/2018
- Study HIC#1604017572